| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.26 | 2e-12 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.24 | 1e-09 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.26 | 2e-07 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.35 | 5e-06 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.32 | 5e-05 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.17 | 6e-05 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | 0.18 | 8e-05 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | AMG-706 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |